. 2014 Apr 7;8:141–153. doi: 10.2147/BTT.S37509

Table 2.

Comparative tolerability of tocilizumab with tumor necrosis factor inhibitors

Registry name	Retention period	Drug survival rate (%)
Registry name	Retention period	TCZ	IFX	ETA	ADA
CORRONA⁴⁵	24 months		63	53	53
LOHREN⁴⁶	2.5 years		56	72	57
SCQM-RA⁴⁷	2.5 years		51	58	61
GISEA⁴⁸	2.5 years		52	65	52
DANBIO⁴⁹,⁵⁰	96 weeks	54
DANBIO⁴⁹,⁵⁰	48 months		41	56	52
BiRD⁵¹	2.5 years	79	47	78	55

Abbreviations: ADA, adalimumab; BiRD, Biologics for Rheumatic Diseases; CORRONA, Consortium of Rheumatology Researchers of North America; DANBIO, Danish Nationwide Rheumatological Database; ETA, etanercept; GISEA, Gruppo Italiano di Studio sulle Early Arthritides; IFX, infliximab; LOHREN, Lombardy Rheumatology Network; SCQM-RA, Swiss Clinical Quality Management for Rheumatoid Arthritis; TCZ, tocilizumab; TNF, tumor necrosis factor.